In the cross-comparison of reported AAbs associated with therapeutic efficacy in NSCLC and our AAbs during the discovery and verification phases, the PPP2R1A AAb exhibited higher levels in non-responders than responders, aligning with Akshay J.'s (30) findings that anti-PPP2R1A AAbs independently predict poor survival in NSCLC after surgery. The gene discussed is PPP2R1A; the disease is non-small cell lung carcinoma.